Different Anti-Vascular Endothelial Growth Factor for Patients With Diabetic Macular Edema: A Network Meta-Analysis
Background: Antiangiogenic therapy with anti-vascular endothelial growth factor (VEGF) is commonly used to treat diabetic macular edema (DME), which can reduce edema, improve vision, and prevent further visual loss. There is little head-to-head trial data to guide the selection of an individual VEGF...
Main Authors: | Xian Wang, Xiaoning He, Fang Qi, Jia Liu, Jing Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-06-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.876386/full |
Similar Items
-
An efficacy comparison of anti-vascular growth factor agents and laser photocoagulation in diabetic macular edema: a network meta-analysis incorporating individual patient-level data
by: Dominic Muston, et al.
Published: (2018-12-01) -
Comparative study between ranibizumab and aflibercept in the management of macular edema caused by diabetes mellitus in age group more than 40 years
by: Abd El-Magid M Tag El-Din
Published: (2019-01-01) -
Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study
by: Yule Xu, et al.
Published: (2017-08-01) -
Efficacy of Aflibercept versus Ranibizumab in the treatment of diabetic macular edema
by: Xiu-Xian Wang, et al.
Published: (2021-12-01) -
Comparison of efficacy of conbercept, aflibercept, and ranibizumab ophthalmic injection in the treatment of macular edema caused by retinal vein occlusion: a Meta-analysis
by: Qiu Xing, et al.
Published: (2023-07-01)